• <menu id="888u4"><menu id="888u4"></menu></menu>
  • Diagnostic Accuracy of 68Ga-PSMA-11 PET/CT and Conventional Imaging for Initial Staging of Intermediate and High-risk Prostate Cancer Patients (the PROCA Study)

    Closed for proposals

    Project Type

    Coordinated Research Project

    Project Code

    E13053

    CRP

    2306

    Approved Date

    9 September 2021

    Status

    Active - Ongoing

    Start Date

    29 October 2021

    Expected End Date

    28 April 2025

    Participating Countries

    Azerbaijan
    Brazil
    Chile
    India
    Italy
    Jordan
    Lebanon
    Malaysia
    Mexico
    Poland
    Türkiye
    Uruguay

    Description

    PSMA PET/CT is a promising method for primary lymph node staging in prostate cancer patients. However, there is lack of enough evidence related to studies with histopathology as a gold standard.
    Cross-sectional anatomical imaging has been recommended for patients with unfavourable intermediate and high-risk prostate cancer for primary lymph node staging across urological guidelines despite known insufficient diagnostic accuracy for both CT and MRI.
    The use of PSMA PET/CT has been evaluated in numerous settings, including primary staging and biochemical recurrence. Some studies have showed good clinical diagnostic performance in those patients where primary lymph node staging is indicated (high-risk and unfavourable intermediate-risk categories), even though some variations in diagnostic accuracy were observed across the trials. However, most studies were very heterogenous, mainly retrospective and of modest size.
    Thus, this CRP will focus on the development of a phase 3, prospective, randomised, and multicentre international study to compare the diagnostic accuracy of PSMA-PET/CT and conventional imaging (CI) with post-prostatectomy histology as gold standard.

    Objectives

    Compare the diagnostic accuracy of PSMA-PET/CT and conventional imaging (CI) with post-prostatectomy histology.

    Specific objectives

    Compare the first-line management impact of PSMA-PET/CT to that of CI.

    Evaluate the prognostic value of PSMA-PET/CT with regards to disease-free status (2 years from accrual of the last patient)

    Compare the cost of each imaging staging strategy

    Compare the diagnostic accuracy of PSMA-PET/CT and conventional imaging (CI) for detecting distant metastases specifically

    Contact the project officer

    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Image CAPTCHA

    Stay in touch

    Newsletter

    午夜爱爱爱爱爽爽爽视频网站